Proteasome inhibitors as experimental therapeutics of autoimmune diseases

Current treatment strategies for rheumatoid arthritis (RA) consisting of disease-modifying anti-rheumatic drugs or biological agents are not always effective, hence driving the demand for new experimental therapeutics. The antiproliferative capacity of proteasome inhibitors (PIs) has received consid...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Arthritis research & therapy Ročník 17; číslo 1; s. 17
Hlavní autoři:	Verbrugge, Sue Ellen, Scheper, Rik J, Lems, Willem F, de Gruijl, Tanja D, Jansen, Gerrit
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 28.01.2015 BioMed Central Ltd
Témata:	Antigen presenting cells Antigens Antirheumatic agents Arthritis, Rheumatoid - drug therapy Autoimmune Diseases - drug therapy Development and progression Drug therapy Health aspects Homeopathy Humans Interleukins Materia medica and therapeutics Medicine Medicine & Public Health Orthopedics Physiological aspects Proteasome Endopeptidase Complex - adverse effects Proteasome Inhibitors - therapeutic use Review Rheumatoid factor Rheumatology Systemic lupus erythematosus T cells Therapeutics Systemic Lupus Erythematosus Major Histocompatibility Complex Class Immune Effector Cell Bortezomib Rheumatoid Arthritis
ISSN:	1478-6354, 1478-6362, 1478-6354, 1478-6362
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!